End-of-day quote
Shanghai S.E.
23:00:00 25/04/2024 BST
|
5-day change
|
1st Jan Change
|
22.2
CNY
|
+0.82%
|
|
+7.56%
|
+1.14%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
23,001
|
15,174
|
14,379
|
8,945
|
8,945
|
9,047
|
-
|
-
|
Enterprise Value (EV)
1 |
23,001
|
15,174
|
14,379
|
8,945
|
8,945
|
9,047
|
9,047
|
9,047
|
P/E ratio
|
1,087
x
|
489
x
|
653
x
|
511
x
|
101
x
|
-56.9
x
|
-117
x
|
740
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
132
x
|
56.3
x
|
33.4
x
|
16.9
x
|
17.1
x
|
12.8
x
|
9.65
x
|
7.39
x
|
EV / Revenue
|
132
x
|
56.3
x
|
33.4
x
|
16.9
x
|
17.1
x
|
12.8
x
|
9.65
x
|
7.39
x
|
EV / EBITDA
|
847
x
|
311
x
|
383
x
|
158
x
|
63.4
x
|
-101
x
|
283
x
|
63.3
x
|
EV / FCF
|
-
|
-
|
-
|
-25.1
x
|
-23.2
x
|
-62.8
x
|
-27.1
x
|
-27.6
x
|
FCF Yield
|
-
|
-
|
-
|
-3.99%
|
-4.31%
|
-1.59%
|
-3.69%
|
-3.63%
|
Price to Book
|
15.9
x
|
10.2
x
|
10.1
x
|
6.49
x
|
5.69
x
|
5.89
x
|
6.2
x
|
6.15
x
|
Nbr of stocks (in thousands)
|
410,000
|
410,000
|
410,721
|
406,971
|
407,537
|
407,537
|
-
|
-
|
Reference price
2 |
56.10
|
37.01
|
35.01
|
21.98
|
21.95
|
22.20
|
22.20
|
22.20
|
Announcement Date
|
27/02/20
|
26/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
173.8
|
269.5
|
430.4
|
529.9
|
523.7
|
705
|
938
|
1,224
|
EBITDA
1 |
27.16
|
48.78
|
37.54
|
56.64
|
141
|
-90
|
32
|
143
|
EBIT
1 |
21.67
|
36.98
|
22.26
|
15.97
|
97.07
|
-160
|
-77
|
16
|
Operating Margin
|
12.47%
|
13.72%
|
5.17%
|
3.01%
|
18.54%
|
-22.7%
|
-8.21%
|
1.31%
|
Earnings before Tax (EBT)
1 |
20.73
|
36.17
|
18.6
|
15.16
|
97.02
|
-160
|
-77
|
16
|
Net income
1 |
19.42
|
31.05
|
21.96
|
17.48
|
88.84
|
-160
|
-77
|
13
|
Net margin
|
11.17%
|
11.52%
|
5.1%
|
3.3%
|
16.96%
|
-22.7%
|
-8.21%
|
1.06%
|
EPS
2 |
0.0516
|
0.0757
|
0.0536
|
0.0430
|
0.2176
|
-0.3900
|
-0.1900
|
0.0300
|
Free Cash Flow
1 |
-
|
-
|
-
|
-356.6
|
-385.9
|
-144
|
-334
|
-328
|
FCF margin
|
-
|
-
|
-
|
-67.29%
|
-73.68%
|
-20.43%
|
-35.61%
|
-26.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
26/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-357
|
-386
|
-144
|
-334
|
-328
|
ROE (net income / shareholders' equity)
|
2.41%
|
2.12%
|
0.02%
|
1.19%
|
5.47%
|
-10.3%
|
-5.2%
|
0.9%
|
ROA (Net income/ Total Assets)
|
1.15%
|
-
|
-
|
0.72%
|
2.91%
|
-4.6%
|
-1.8%
|
0.3%
|
Assets
1 |
1,691
|
-
|
-
|
2,414
|
3,050
|
3,478
|
4,278
|
4,333
|
Book Value Per Share
2 |
3.530
|
3.640
|
3.450
|
3.390
|
3.860
|
3.770
|
3.580
|
3.610
|
Cash Flow per Share
2 |
-0.0600
|
0.2300
|
0.3000
|
0.1100
|
-0.3800
|
0.1100
|
0.1900
|
0.3500
|
Capex
1 |
133
|
336
|
288
|
400
|
229
|
172
|
394
|
435
|
Capex / Sales
|
76.54%
|
124.79%
|
67.01%
|
75.46%
|
43.65%
|
24.4%
|
42%
|
35.54%
|
Announcement Date
|
27/02/20
|
26/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Last Close Price
22.2
CNY Average target price
26.33
CNY Spread / Average Target +18.60% Consensus |
1st Jan change
|
Capi.
|
---|
| +1.14% | 1.25B | | +5.31% | 70.44B | | +10.97% | 8.94B | | -16.83% | 4.75B | | +43.48% | 4.5B | | +3.20% | 3.85B | | +18.82% | 2.38B | | -21.36% | 2.34B | | -29.67% | 2.2B | | +8.38% | 1.96B |
Specialty & Advanced Pharmaceuticals
|